Methicillin-resistant Staphylococcus
aureus (MRSA) is a resistant form of bacteria that stakes an infamous claim to
causing infection in a variety of areas on the human body. Commonly, MRSA
manifests itself in the form of boils, sores or abscesses. The MRSA bacteria is
unique among staph infections because it is resistant to today’s pervasively
prescribed forms of antibiotics. MRSA skin infections occupy an extenuating
range from elementary to life-threatening. Due to being knowns as unpredictable
and difficult to treat, MRSA is widely referred to in clinical circles as a
“Superbug.”
MRSA in the form of skin rashes spreads
through the resistant bacteria entering the body. While staph is common, it can
cause infection when it gets into the blood via cut in the skin. This form of
bacteria has evolved through generations as cultures have over prescribed and
subsequently overused antibiotics to treat common colds, viruses and influenza
(the flu). Even when antibiotics are appropriately used to treat bacterial infections,
they cause bacteria to adjust, making them more resistant. With the MRSA
constantly changing, it complicates the task for researchers to develop
antibiotics that will effectively fight it.
The symptoms of MRSA found on the skin
are commonly red and swollen. These infections can also look like pimples or
spider bites and are pus-filled. Left untreated, infection can spread to the
blood. As the infected blood moves through the body, infection of the joints,
bones, heart valves and lungs can occur and result in organ failure. Other
symptoms come in the form of chills, fever and cough. Patients with weak immune
systems, those who live and work in care centers, such as day care centers,
jails, and retirement homes are at particular risk.
Zenosense Inc. (OTCQB: ZENO) holds an
exclusive global license agreement for developing and marketing medical devices
within hospitals and primary healthcare facilities. The company’s devices
target the early detection of both deadly bacteria like MRSA and some cancers
through detection within a person’s breath. Two devices are currently being
developed. One is a device intended to detect the MRSA “Super-Bug” and the
other is intended to detect Lung Cancer. Through the commonly used Electronic
Nose technology platform, the ZENO devices are being designed to detect
volatile organic compounds (VOC’s) present in the exhaled breath of patients.
Company experts in the fields of
nanotechnology, sensors, high-level mathematics, molecular biology and
biochemistry are currently engaged in work necessary for product development.
For more information on the company,
visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment